Correlation of G1 cyclins and cyclin-dependent kinase inhibitors relative to human papillomavirus infection in the uterine cervical lesions

International Journal of Surgical Pathology

Volumn 7, Issue 2, 1999, Pages 61-71

  Cho, Nam Hoon ^a,c   Ahn, Hee Jeong ^b   Kim, Young Tae ^a   Kim, Jae Wook ^a  

^a Yonsei University   (South Korea)

^b CHA University   (South Korea)

^c NONE   (United States)

Author keywords

Cyclin dependent kinase inhibitors; G1 cyclin; Human papillomavirus

Indexed keywords

CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E; CYCLINE; PROTEIN P16; PROTEIN P21; PROTEIN P27;

ARTICLE; CELL CYCLE G1 PHASE; CELL TRANSFORMATION; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA IN SITU; UTERUS CARCINOMA; VIRUS INFECTION; WART VIRUS;

EID: 2442744585     PISSN: 10668969     EISSN: None     Source Type: Journal    
DOI: 10.1177/106689699900700201     Document Type: Article

References (41)

1. zur Hausen H, de Villiers EM. Human papilloma viruses. Ann Rev Microbiol 48:427-447, 1994
2. Herrington CS. Human papillomaviruses and cervical neoplasia. Interaction of hPV with other factors. J Clin Pathol 48:1-6, 1995
3. Pines J. Cyclins, CDKs and cancer. Semin Cancer Biol 6:63-72, 1995
4. Lukas J, Muller H, Bartkova J, et al. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1. J Cell Diol 125:625-638, 1994
5. Dulic V, Lees E, Reed SI. Association of human cyclin E with a periodic G1-S phase protein kinase. Science 257:1958-1962, 1992
6. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78:67-74, 1994
7. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55:2910-2919, 1995
8. WAF1/CIP1 in nonneoplastic mucosa and neoplasia of the stomach: Relationship with p53 status and proliferative activity. J Pathol 180:122-128, 1996
9. WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 27:60-66, 1997
10. Serrano M, Hannnon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/Cdk4. Nature 366:704-707, 1993
11. Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y. Frequent somatic mutation of the MTS1/CDK4I gene in esophageal squamous cell carcinoma. Cancer Res 54:3396-3397, 1994
12. Caldas C, Hahn SA, da Costa LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hrubam RH, Yeo CJ, Kern SE. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocaricnoma. Nat Genet 8:27-32, 1994
13. INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995
14. Waga S, Hannnon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-577, 1994
15. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 366:701-704, 1993
16. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell W. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387-400, 1995
17. Hall M, Bates S, Peters G. Evidence for different models of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins. Oncogene 11:1581-1588, 1995
18. KIP1, a cyclin-dependcnt kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78:59-66, 1994
19. Cho NH, YT Kim, JW Kim. Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol 6:339-347, 1997
20. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. Waf1, a potential mediator of p53 tumor suppression. Cell 75:817-825, 1993
21. KIP1 gene to 12p13 and its analysis in leukemias. Cancer Res 55:1206-1210, 1995
22. KIP1: Chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 55:1211-1214, 1995
23. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A, Harper JW, Elledge SJ. p57kip2, a structually distinct member of the p21cip1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 9:650-662, 1995
24. Dulic V, Kaufmann WK, Wilson SJ, Tlsty TD, Lees E, Harper JW, Elledge SJ, Reed SI. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013-1023, 1994
25. El-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Kackman J, Pietenpol JA, Burrell M, Hill DE, Wang Y, Wilman KG, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B. Waf1/Cip1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169-1174, 1994
26. Lo KW, Huang DP, Lau KM. p16 gene alterations in nasopharyngeal carcinoma. Cancer Res 55:2039-2043, 1995
27. Kamb A, Gruis N, Feldhaus J, Liu Q, Harshnman K, Tavtigian S, Stockert E, Day R, Johnson B, Skolnick M. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-439, 1994
28. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753-756, 1994
29. Zhang SY, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinomas cell lines than in primary tumors of the head and neck. Cancer Res 54:5050-5053, 1994
30. INK4 in human cancer. Proc Natl Acad Sci USA 91:11045-11049, 1994
31. Cairns P, Mao L, Merlo A, Lee DJ, Schwab D, Eby Y, Tokino K, van der Riet P, Blaugrund J, Sidransky D. Rates of p16 (MTS1) mutations in primary tumor with 9p loss. Science 265:415-416, 1994
32. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 56:3630-3633, 1996
33. Geradts J, Kratzke RA, Niehans GA, Lincoln CE. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2.MTS1) product p16 INK4 in archival human solid tumors: Correlation with retinoblastoma protein expression. Cancer Res 55:6006-6011, 1995
34. Vousden KH. Regulation of the cell cycle by viral oncoproteins. Sem Cancer Biol 6:109-116, 1995
35. Yeager T, Stadler W, Belair C, Puthenveettiil J, Olopade O, Reznikoff C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res 55:493-497, 1995
36. Sakaguchi M, Fujii Y, Hirabayashi H, Yoon H, Komoto Y, Oue T, Kusafuka T, Okada A, Matsuda H. Inverselt correlated expression of p16 and Rb protein in non-small cell lung cancers: An immunohistochemical study. Int J Cancer 65:442-445, 1996
37. Tam SW, Shay JW, Pagano M. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16 ink4. Cancer Res 54:5816-5820, 1994
38. INK4 and retinoblastoma tumor-suppresor genes occur in distinct subsets of human cancer cell lines. Int J Cancer 61:115-120, 1995
39. Nakao Y, Yang X, Yokoyama M, Ferenczy A, Tang S-C, Pater MM, Pater A. Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. Int J Cancer 78:1410-1416, 1997
40. Reznikoff CA, Yeager TR, Belair CD, Savelieva E, Puthenveettii JA, Stadler WM. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res 56:2886-2890, 1996
41. WAF1/CIP1 in human brain tumors. Oncogene 11:2021-2028, 1995